ID

31113

Description

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR; ODM derived from: https://clinicaltrials.gov/show/NCT00567359

Link

https://clinicaltrials.gov/show/NCT00567359

Keywords

Versions (1)
  1. 7/21/18 7/21/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 21, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-small Cell Lung Cancer NCT00567359

English

Eligibility Non-small Cell Lung Cancer NCT00567359

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
pathologically confirmed diagnosis of nsclc of adenocarcinoma histology
Description

Non-Small Cell Lung Carcinoma | Adenocarcinoma Histology

Data type

boolean

Alias
UMLS CUI [1]
C0007131
UMLS CUI [2,1]
C0001418
UMLS CUI [2,2]
C4048239
stage ia-b, iia-b, or iiia by the american joint committee on cancer 7th edition staging criteria
Description

TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1]
C3258246
patients must have undergone surgical resection with curative intent within 6 months of enrollment
Description

Excision Curative

Data type

boolean

Alias
UMLS CUI [1,1]
C0728940
UMLS CUI [1,2]
C1276305
sufficient tumor tissue available for egfr mutation analysis
Description

Availability of Tumor tissue Sufficient | EGFR gene mutation Analysis

Data type

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0475358
UMLS CUI [1,3]
C0205410
UMLS CUI [2,1]
C3266992
UMLS CUI [2,2]
C0002778
at least one of the following patient characteristics: previously detected deletion 19 or l858r egfr mutation, female sex, history of never smoking, or asian/pacific rim ethnicity (to be enrolled in the screening portion of trial).
Description

Client Characteristics | EGFR exon 19 deletion | Point mutation in exon 21 (L858R) | Gender | Never smoked tobacco | Asians

Data type

boolean

Alias
UMLS CUI [1]
C0815172
UMLS CUI [2]
C3889117
UMLS CUI [3]
C3888903
UMLS CUI [4]
C0079399
UMLS CUI [5]
C0425293
UMLS CUI [6]
C0078988
18 years of age or older
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
tumor samples must have either exon 19 deletion mutations or the exon 21 l858r point mutation
Description

Tumor tissue sample EGFR exon 19 deletion | Tumor tissue sample Point mutation in exon 21 (L858R)

Data type

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C3889117
UMLS CUI [2,1]
C0475358
UMLS CUI [2,2]
C3888903
ecog performance status of 0,1, or 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate organ function as outlined in protocol
Description

Organ function

Data type

boolean

Alias
UMLS CUI [1]
C0678852
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
radiographic evidence of recurrent nsclc prior to erlotinib treatment
Description

Non-small cell lung cancer recurrent Radiography | erlotinib

Data type

boolean

Alias
UMLS CUI [1,1]
C0278517
UMLS CUI [1,2]
C0034571
UMLS CUI [2]
C1135135
confirmed t790m resistance mutation in the primary tumor sample
Description

EGFR T790M Resistance Mutation | Tumor tissue sample Primary

Data type

boolean

Alias
UMLS CUI [1,1]
C3274192
UMLS CUI [1,2]
C1514892
UMLS CUI [1,3]
C0026882
UMLS CUI [2,1]
C0475358
UMLS CUI [2,2]
C0205225
prior exposure to egfr tyrosine kinase inhibitors
Description

Exposure to EGFR Tyrosine Kinase Inhibitors

Data type

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C1443775
known hypersensitivity to erlotinib, gefitinib, or any closely related drug
Description

Hypersensitivity Erlotinib | Hypersensitivity Gefitinib | Hypersensitivity Pharmaceutical Preparations Related

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1135135
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1122962
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0013227
UMLS CUI [3,3]
C0439849
pregnant or breastfeeding women
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
any evidence of clinically active interstitial lung disease
Description

Lung Diseases, Interstitial

Data type

boolean

Alias
UMLS CUI [1]
C0206062
current use of enzyme-inducing anti-epileptic drugs, including carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, and primidone
Description

Antiepileptic Agents Enzyme Inducing | Carbamazepine | oxcarbazepine | Phenytoin | fosphenytoin | Phenobarbital | Primidone

Data type

boolean

Alias
UMLS CUI [1,1]
C0003299
UMLS CUI [1,2]
C0014442
UMLS CUI [1,3]
C0205263
UMLS CUI [2]
C0006949
UMLS CUI [3]
C0069751
UMLS CUI [4]
C0031507
UMLS CUI [5]
C0244656
UMLS CUI [6]
C0031412
UMLS CUI [7]
C0033148
evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
Description

Disease Study Subject Participation Status Unfavorable | Laboratory finding Study Subject Participation Status Unfavorable

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C3640815
UMLS CUI [2,1]
C0587081
UMLS CUI [2,2]
C2348568
UMLS CUI [2,3]
C3640815
use of any non-fda approved or investigational agent within 2 weeks of enrolling onto the trial, or failure to recover from the side effects of any of these agents
Description

Drugs, Non-Prescription | Investigational New Drugs | Side effects Pharmaceutical Preparations Recovery failed

Data type

boolean

Alias
UMLS CUI [1]
C0013231
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C0879626
UMLS CUI [3,2]
C0013227
UMLS CUI [3,3]
C2004454
UMLS CUI [3,4]
C0231175
Back to the top of the page

Similar models

Eligibility Non-small Cell Lung Cancer NCT00567359

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma | Adenocarcinoma Histology
Item
pathologically confirmed diagnosis of nsclc of adenocarcinoma histology
boolean
C0007131 (UMLS CUI [1])
C0001418 (UMLS CUI [2,1])
C4048239 (UMLS CUI [2,2])
TNM clinical staging
Item
stage ia-b, iia-b, or iiia by the american joint committee on cancer 7th edition staging criteria
boolean
C3258246 (UMLS CUI [1])
Excision Curative
Item
patients must have undergone surgical resection with curative intent within 6 months of enrollment
boolean
C0728940 (UMLS CUI [1,1])
C1276305 (UMLS CUI [1,2])
Availability of Tumor tissue Sufficient | EGFR gene mutation Analysis
Item
sufficient tumor tissue available for egfr mutation analysis
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C0205410 (UMLS CUI [1,3])
C3266992 (UMLS CUI [2,1])
C0002778 (UMLS CUI [2,2])
Client Characteristics | EGFR exon 19 deletion | Point mutation in exon 21 (L858R) | Gender | Never smoked tobacco | Asians
Item
at least one of the following patient characteristics: previously detected deletion 19 or l858r egfr mutation, female sex, history of never smoking, or asian/pacific rim ethnicity (to be enrolled in the screening portion of trial).
boolean
C0815172 (UMLS CUI [1])
C3889117 (UMLS CUI [2])
C3888903 (UMLS CUI [3])
C0079399 (UMLS CUI [4])
C0425293 (UMLS CUI [5])
C0078988 (UMLS CUI [6])
Age
Item
18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Tumor tissue sample EGFR exon 19 deletion | Tumor tissue sample Point mutation in exon 21 (L858R)
Item
tumor samples must have either exon 19 deletion mutations or the exon 21 l858r point mutation
boolean
C0475358 (UMLS CUI [1,1])
C3889117 (UMLS CUI [1,2])
C0475358 (UMLS CUI [2,1])
C3888903 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of 0,1, or 2
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
adequate organ function as outlined in protocol
boolean
C0678852 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Non-small cell lung cancer recurrent Radiography | erlotinib
Item
radiographic evidence of recurrent nsclc prior to erlotinib treatment
boolean
C0278517 (UMLS CUI [1,1])
C0034571 (UMLS CUI [1,2])
C1135135 (UMLS CUI [2])
EGFR T790M Resistance Mutation | Tumor tissue sample Primary
Item
confirmed t790m resistance mutation in the primary tumor sample
boolean
C3274192 (UMLS CUI [1,1])
C1514892 (UMLS CUI [1,2])
C0026882 (UMLS CUI [1,3])
C0475358 (UMLS CUI [2,1])
C0205225 (UMLS CUI [2,2])
Exposure to EGFR Tyrosine Kinase Inhibitors
Item
prior exposure to egfr tyrosine kinase inhibitors
boolean
C0332157 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
Hypersensitivity Erlotinib | Hypersensitivity Gefitinib | Hypersensitivity Pharmaceutical Preparations Related
Item
known hypersensitivity to erlotinib, gefitinib, or any closely related drug
boolean
C0020517 (UMLS CUI [1,1])
C1135135 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1122962 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnant or breastfeeding women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Lung Diseases, Interstitial
Item
any evidence of clinically active interstitial lung disease
boolean
C0206062 (UMLS CUI [1])
Antiepileptic Agents Enzyme Inducing | Carbamazepine | oxcarbazepine | Phenytoin | fosphenytoin | Phenobarbital | Primidone
Item
current use of enzyme-inducing anti-epileptic drugs, including carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, and primidone
boolean
C0003299 (UMLS CUI [1,1])
C0014442 (UMLS CUI [1,2])
C0205263 (UMLS CUI [1,3])
C0006949 (UMLS CUI [2])
C0069751 (UMLS CUI [3])
C0031507 (UMLS CUI [4])
C0244656 (UMLS CUI [5])
C0031412 (UMLS CUI [6])
C0033148 (UMLS CUI [7])
Disease Study Subject Participation Status Unfavorable | Laboratory finding Study Subject Participation Status Unfavorable
Item
evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
boolean
C0012634 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C3640815 (UMLS CUI [1,3])
C0587081 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C3640815 (UMLS CUI [2,3])
Drugs, Non-Prescription | Investigational New Drugs | Side effects Pharmaceutical Preparations Recovery failed
Item
use of any non-fda approved or investigational agent within 2 weeks of enrolling onto the trial, or failure to recover from the side effects of any of these agents
boolean
C0013231 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0879626 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
C2004454 (UMLS CUI [3,3])
C0231175 (UMLS CUI [3,4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial